Philip J. Larsen, MD PhD, is the CEO of Sixpeaks Bio AG. Philip has gained R&D leadership experience from positions in several global pharmaceutical enterprises (NovoNordisk, Eli Lilly, AstraZeneca, Grünenthal, Sanofi, Bayer). Before taking the helm at Sixpeaks Bio, Philip was the senior vice president, Global Head of Pharma Research and Early Development Precision Medicine at Bayer AG. At Bayer he was overseeing research, translational medicine, and early clinical development with accompanying portfolio and investment responsibilities in Bayer’s core areas therapeutic area and portfolio responsibilities: cardiovascular medicine, nephrology, inflammation, and reproductive endocrinology. Philip has a longstanding experience form discovery and drug development in the area of anti-obesity agents. Under his leadership as Chief Scientific Officer for Diabetes and Obesity at Eli Lilly and Co., the dual incretin agonist programs that led to tirzepatide and mazdutide were initiated. Philip is an MD PhD from the University of Copenhagen. After four years of medical practice (internal medicine, neurology) he went from academic medicine to life sciences industry. In addition, Philip holds a Doctor of Medicine degree from the University of Copenhagen and a PhD in neuroscience.